Term
|
Definition
| delusion, halluc, disorganized thought/speech/behavior, catatonia, negs-flat, alogia, avolition, anhedonia |
|
|
Term
| time period in which to evaluate schizophrenic sx? |
|
Definition
|
|
Term
| postulated mech of schizophrenia? |
|
Definition
|
|
Term
|
Definition
| chlorpromazine, thor, thiorid, fluphen, trifluroper, perphen |
|
|
Term
|
Definition
|
|
Term
| conventinal antipsychotics |
|
Definition
| phenothiazines, thioxanthines, butyrophenones |
|
|
Term
| gen action of conv antipsychotics? |
|
Definition
|
|
Term
| where in the dopaminergic system are the anti-psychotic effects of TAP meds mediated? |
|
Definition
|
|
Term
| where in the DAergic system are the negative SE of TAP meds mediated? |
|
Definition
|
|
Term
| what DAergic system is responsible for the EPS sx assoc w/ typ antipsychotics? |
|
Definition
|
|
Term
|
Definition
| D2 blockade of nigrostriatal sys |
|
|
Term
|
Definition
| Park, Dystonia, Akathesia |
|
|
Term
| how can EPS be treated pharmacologically? |
|
Definition
| b-blocker, benzo, anti-chol(benzotropine), pro-DA med |
|
|
Term
| what is the classic chronic EPS? |
|
Definition
| tardive dyskinesia (invol choreoathetotisms) |
|
|
Term
| what are the tuberinfundibular SE of typical antipsychotics? |
|
Definition
|
|
Term
| what are the musc SE of TAPs? |
|
Definition
|
|
Term
| which types of TAPs are more likely to cause anti-cholinergic effects? |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| disadvantages of TAPs for schizophrenia? |
|
Definition
| not all respond, significant relapse, no effect on neg sx |
|
|
Term
| what are the adrenergic SE of TAP? |
|
Definition
|
|
Term
| what are the histaminergic SE of TAP? |
|
Definition
|
|
Term
| which types of TAP are more likely to give you EPS? |
|
Definition
|
|
Term
| what is the source of DA for the mesolimbic/mesocortical DAergic systems? |
|
Definition
|
|
Term
|
Definition
| reduced EPS, reduced PRL, some degree of efficacy against neg sx |
|
|
Term
|
Definition
| mod-hi 5HT2AR blockade, lower potency D2 blockade |
|
|
Term
|
Definition
| risperidone, ziprasidone, quetiapine, olanzapine, clozapine |
|
|
Term
| which ATAP has the highest 5HT2A:D2 ratio? |
|
Definition
|
|
Term
| hypothesized mech of ATAP at neostriatal/mesolimbic |
|
Definition
| serotonin blockade may enhance DA release in basal ganglia (minimizes D2 blockade) |
|
|
Term
| hypothesized mech of ATAP at mesocortical sys? |
|
Definition
| serotonin blockade may normalize cortical fxn |
|
|
Term
| risk of EPS greater with risperdone/clozapine? |
|
Definition
|
|
Term
| risk of non-EPS SE greater with risperdone/clozapine? |
|
Definition
|
|
Term
| prominent SE of risperdone? |
|
Definition
|
|
Term
| prominent SE of clozapine? |
|
Definition
|
|
Term
| prominent SE of clozapine and olanzapine? |
|
Definition
| weight gain, gluc intol, hyperlip |
|
|
Term
| prominent SE of quetiapine? |
|
Definition
|
|
Term
| prominent SE of ziprasidone? |
|
Definition
| QT elongation, arrhythmia |
|
|
Term
|
Definition
| partial agonist of D2 (lo/hi environ), antagonist of 5HT2AR |
|
|
Term
| advantage of aripiprazole? |
|
Definition
| doesnt contribute to metabolic syndrome |
|
|
